Simulations Plus, Inc. (NASDAQ:SLP) Director Sells $678,200.00 in Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total transaction of $678,200.00. Following the sale, the director now owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Simulations Plus Stock Performance

Shares of SLP opened at $35.50 on Wednesday. The firm’s 50-day simple moving average is $30.56 and its two-hundred day simple moving average is $32.42. Simulations Plus, Inc. has a fifty-two week low of $24.00 and a fifty-two week high of $51.22. The stock has a market cap of $713.20 million, a PE ratio of 88.75 and a beta of 0.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company increased its position in shares of Simulations Plus by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 6,391 shares of the technology company’s stock valued at $311,000 after acquiring an additional 456 shares in the last quarter. Azzad Asset Management Inc. ADV raised its stake in shares of Simulations Plus by 68.7% in the third quarter. Azzad Asset Management Inc. ADV now owns 13,505 shares of the technology company’s stock worth $432,000 after purchasing an additional 5,498 shares during the last quarter. InTrack Investment Management Inc lifted its holdings in shares of Simulations Plus by 5.9% during the third quarter. InTrack Investment Management Inc now owns 33,543 shares of the technology company’s stock valued at $1,074,000 after purchasing an additional 1,878 shares in the last quarter. Kings Path Partners LLC boosted its position in shares of Simulations Plus by 19.2% during the third quarter. Kings Path Partners LLC now owns 22,560 shares of the technology company’s stock valued at $722,000 after buying an additional 3,633 shares during the last quarter. Finally, nVerses Capital LLC increased its holdings in Simulations Plus by 1,100.0% in the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the technology company’s stock worth $38,000 after buying an additional 1,100 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on SLP shares. KeyCorp increased their price objective on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Stephens started coverage on shares of Simulations Plus in a research report on Friday, November 15th. They issued an “overweight” rating and a $39.00 target price for the company. BTIG Research reduced their price target on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. StockNews.com downgraded shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Finally, William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Simulations Plus presently has an average rating of “Moderate Buy” and an average price target of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.